Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 12/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12230697 | 0.95 | QPCT (0.80) | QPCTCYP2C19IP6K1CNR2 | |
| SCHEMBL2546266 | 0.90 | QPCT (0.72) | QPCTCYP2C19IP6K1CNR2 | |
| SCHEMBL2540372 | 0.86 | QPCT (0.64) | QPCTCYP2C19MEN1KMT2AALDH1A1 | |
| SCHEMBL2537533 | 0.86 | QPCT (0.83) | QPCTCYP2C19MEN1NPC1RAB9A | |
| SCHEMBL2546370 | 0.86 | QPCT (0.83) | QPCTMEN1NPC1RAB9AKMT2A | |
| SCHEMBL2539323 | 0.83 | QPCT (0.58) | QPCTMEN1NPC1RAB9AKMT2A | |
| SCHEMBL12286798 | 0.81 | QPCT (0.59) | QPCTALDH1A1IP6K1TDP1 | |
| SCHEMBL2542024 | 0.81 | QPCT (0.59) | QPCTIP6K1 | |
| SCHEMBL2545562 | 0.81 | QPCT (0.63) | QPCTCYP2C19TSHRIP6K1 | |
| SCHEMBL2543554 | 0.81 | QPCT (0.59) | QPCTIP6K1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560953-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-01-06 | — | — | EP | claimed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | claimed |
| EP-2560953-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-01-06 | — | — | EP | disclosed |
| EP-2560953-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-01-06 | — | — | EP | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2560953-A2 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262388-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | QPCT 2/4885CYP2C19 1338/4885MEN1 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.